Spike Pharmaceuticals Helps Sink Quality Resources
Release time:
2020-08-14
Peak Pharmaceutical Helps Sinking of High-quality Resources
News 9# July 24 - 25 , the "Summit Forum on Helping Sinking of High-quality Resources and" Two Searches' "activity co-organized by Peak Pharmaceutical was held in Shengzhou People's Hospital, Zhejiang Province.
This event was hosted by the China County Health Development Research Center and the "China County Health" magazine. It attracted leaders and academic experts from the National Family Planning Commission and local family planning departments, as well as from Inner Mongolia, Anhui, Shandong, Jiangxi, Nearly a hundred county-level hospital department directors and scholars from dozens of county hospitals including Heilongjiang and Heilongjiang participated, this paper discusses the problems of "how to improve the service ability of county-level hospitals" and "how to undertake the county-level hospitals under the general trend of hierarchical diagnosis and treatment.
9 25 , at the seminar on "Exploration and Progress: Implementing Graded Diagnosis and Treatment and Accelerating the Rapid Improvement of Service Level in County and Municipal Hospitals", Huang Jinlong said that graded diagnosis and treatment and the sinking of high-quality medical resources are the strategic choices for the country to accelerate the development of medical and health undertakings and the only way to gradually realize the lofty goal of basic medical and health services for everyone. Medical and health services are directly related to the health of the people. It is necessary to promote the downward shift of the focus of medical and health work, the sinking of medical and health resources, promote the equalization of basic public services in urban and rural areas, and provide the people with safe, effective, convenient and cheap public health and basic medical services, and truly solve the problem. It is difficult and expensive for the grassroots to see a doctor. As a national high-tech enterprise, Peak Pharmaceutical is willing to join hands with related industries to discuss pharmaceutical and medical development plans. The pharmaceutical company will also cooperate with the "Chinese Journal of Pharmacy" and "Chinese Journal of Hospital Pharmacy" to actively participate in the continuing education and training of some grassroots medical staff, and make a modest contribution to improving the professional level of medical professionals. During the
meeting, the relevant persons in charge of the pharmaceutical sales company and the participating experts conducted academic exchanges to share effective, high-quality and low-cost drugs, and at the same time introduced the achievements of drug research and development to the experts, and through the experts in medical practice The clinical experience in China in turn guides the direction of product development. (Pharmaceutical Sales Company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page